Loading
Fulcrum Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Jul 2026.
Fulcrum Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Fulcrum Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Fulcrum Therapeutics, Inc. logged 14 filings by 6 insiders.
The record shows 6 purchases on the open market worth €1.3M, made by 1 insider, against 7 sales worth €16.4M by 4 insiders. No amount is published for 1 filing, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 major shareholder. Biggest ticket of the year: €15.8M, sold by RA Capital Management, L.P. and made public on 10 December 2025.
With 14 filings in twelve months, the company is quieter than the median of 19 filings across the 5,810 companies we follow on the same exchange. Our records for Fulcrum Therapeutics, Inc. go back to 2021, with 16 purchases and 12 sales on the open market in total.
The last purchase on record was published on 20 July 2026, which is 90 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
43
Thresholds
n/a
Buy Volume
€31M
16 ops. · all time
Sell Volume
€17M
12 ops. · all time
Who traded when
BuySaleKevin Tang6 buys
Robert J. Gould4 sales
Alan Ezekowitz1 sale
Curtis Gale Oltmans1 sale
Greg Tourangeau1 sale
RA Capital Management, L.P.1 sale
Since the insiders bought
- -0.3%Entry US$3.68 · Close 14 Oct 2026 US$3.67
- -53.2%Entry US$10.48 · Close at T+365 US$4.90
- -53.2%Entry US$10.48 · Close at T+365 US$4.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.67
Analyst consensus
3 analysts3.20/5
US$3.00Target US$3.67(-0%)US$4.00
Income statement
EBITDA-US$83.4M
Net income-US$74.9M0.0% margin
Valuation
PER (forward)-6.7x
P/Book0.9x
Beta2.63
Balance sheet & cash
Market capUS$280.3M
Total debtUS$6.4M
Free Cash Flow-US$60.4M
Debt / Equity2%
Profitability & ownership
ROE-32.4%
ROA-19.6%
% insiders3.3%
% institutions103.1%
Last declaration on 20 July 2026
Declarations43 total
50,945 shares@ US$3.520.062% mcap12.1% of flowCommon StockSEC:0001178579-26-000016:1
Canonical exit: 15 Oct 2026 (T+90)
116,671 shares@ US$3.560.14% mcap27.9% of flowCommon StockSEC:0001178579-26-000016:0
Canonical exit: 14 Oct 2026 (T+90)
107,377 shares@ US$3.560.13% mcap25.7% of flowCommon StockSEC:0001178579-26-000014:3
Canonical exit: 13 Oct 2026 (T+90)
75,952 shares@ US$3.580.095% mcap18.4% of flowCommon StockSEC:0001178579-26-000014:2
Canonical exit: 12 Oct 2026 (T+90)
12,966 shares@ US$3.540.016% mcap3.1% of flowCommon StockSEC:0001178579-26-000014:0
Canonical exit: 11 Oct 2026 (T+90)
53,651 shares@ US$3.560.067% mcap12.9% of flowCommon StockSEC:0001178579-26-000014:1
Canonical exit: 12 Oct 2026 (T+90)
18,000 sharesCommon StockSEC:0001193125-26-290622:0
18,000 shares@ US$3.61100.0% of flowCommonSEC144:0001950047-26-006549
15,000 shares@ US$10.87260.055% mcap8.7% of flowCommon StockSEC:0001193125-26-037606:0
15,000 shares@ US$10.72380.054% mcap8.5% of flowCommon StockSEC:0001193125-26-037573:0
15,000 shares@ US$11.87260.060% mcap9.5% of flowCommon StockSEC:0001193125-26-004572:0
3,452 shares@ US$12.9282.2% of flowCommon StockSEC:0001193125-25-322740:0
1,377,020 shares@ US$13.3335.5% of flowCommon StockSEC:0001231919-25-000596:0
15,000 shares@ US$11.0339.0% of flowCommon StockSEC:0001193125-25-291392:0
498 shares@ US$5.064.0% of flowCommon StockSEC:0000950170-25-068038:0
8,500,000 sharesCommon StockSEC:0001415889-24-022127:0
150,000 shares@ US$3.2750.0% of flowCommon StockSEC:0000950170-24-081949:0
236 shares@ US$7.763.0% of flowCommon StockSEC:0000950170-24-056947:0
4,884 shares@ US$11.715591.9% of flowCommon StockSEC:0000950170-24-028827:0
43,360 shares@ US$11.347550.0% of flowCommon StockSEC:0000950170-24-025933:0
Canonical exit: 2 Jun 2024 (T+90)
210 shares@ US$3.311.1% of flowCommon StockSEC:0000950170-23-021245:0
1,923,076 shares@ US$13.0051.9% of flowCommon StockSEC:0001104659-23-006213:0
Canonical exit: 20 Apr 2023 (T+90)
6,766 shares@ US$15.005.9% of flowCommon StockSEC:0000899243-23-001803:0
122,334 shares@ US$7.02761.8% of flowCommon StockSEC:0001104659-23-001881:0
Canonical exit: 4 Apr 2023 (T+90)
4,089 shares@ US$5.99410.1% of flowCommon StockSEC:0001104659-22-130982:0
Canonical exit: 27 Mar 2023 (T+90)
25 of 43 declarations
About Fulcrum Therapeutics, Inc.
Geographically, Fulcrum’s operating footprint is concentrated in the Boston/Cambridge biotech cluster, where it maintains its headquarters and laboratory space. That location provides access to talent, academic networks, and the broader U.S. life sciences ecosystem, but the company remains primarily a research and development organization with limited commercial infrastructure. Recent highlights include positive updates from the Phase 1b PIONEER study of pociredir in SCD, plans to advance toward a potential registration-enabling trial in the second half of 2026, and a stronger cash position at the end of 2025 following a public equity offering. Overall, Fulcrum remains a high-risk, high-upside rare-disease biotech listed on the NASDAQ Global Market in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
